Head and Neck Squamous Cell Carcinoma (HNSCC) Clinical Trial
— PICHOfficial title:
Induction Therapy With Docetaxel, Cisplatin, 5-Fluoro Uracil and Pembrolizumab in Untreated Locally-advanced Unresectable Squamous Cell Head and Neck Carcinoma (Pembrolizumab and Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma. PICH Study)
Verified date | March 2019 |
Source | Centre Antoine Lacassagne |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Non-randomized phase I/II, open-labeled clinical study, 1-arm, multicenter, of docetaxel (T),
cisplatin (P), 5-fluorouracil (F) and pembrolizumab every 21 days for 3 cycles followed by
radiotherapy (RT) combined with carboplatin in untreated unresectable locally-advanced Head
and Neck Squamous Cell Carcinoma (HNSCC).
The TPF and pembrolizumab combination will be called TP²F.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | March 12, 2019 |
Est. primary completion date | March 12, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility |
Inclusion Criteria: To be eligible for participation in this trial, the subject should fulfill the following criteria: 1. Age > or = 18 and < 70 years years at the time of signing informed consent, 2. Histologically or cytologically confirmed head and neck squamous-cell carcinoma (oral cavity, oropharynx and hypopharynx) with locoregionally-advanced disease stage III or IV without metastasis, previously untreated, 3. Measurable disease based on RECIST 1.1, 4. Performance status of 0 or 1 on the ECOG Performance Scale, 5. Adequate organ function described in protocol section 4.2 - Inclusion criteria, 6. Tumors considered unresectable by a multidisciplinary team, 7. Available biopsy sample and HPV status, 8. Female subjects of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required, 9. Female subjects of childbearing potential should be willing to use 2 methods of birth control or be surgically sterile, or abstain from heterosexual activity for the course of the study through 180 days after the last dose of study medication. Subjects of childbearing potential are those who have not been surgically sterilized or have not been free from menses for > 1 year, 10. Male subjects should agree to use an adequate method of contraception or abstain from heterosexual activity starting with the first dose of study therapy through 180 days after the last dose of study therapy, 11. Patient willing and able to provide written informed consent/assent for the trial, 12. Patient affiliated with a health insurance system. Exclusion criteria The subject should not enter into the study if any of the following exclusion criteria are fulfilled: 1. Tumors of the nasopharynx, larynx and the nasal and paranasal cavities, 2. Hemorrhagic tumors, Protocol PICH_version 2.0 of 02 May 2018 Page 10 sur 127 3. Currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks prior to the first dose of treatment, 4. Before the first dose of trial treatment: a) Had major surgery (< 4 weeks prior to the first dose), Note: If subject received major surgery, he must have recovered adequately from the toxicity and/or complications from the intervention before starting therapy, 5. Diagnosis of immunodeficiency (including HIV 1/2 positivity) or currently received systemic steroid therapy with dose superior to 10 mg/day of prednisone or equivalent or any other form of immunosuppressive therapy, within 7 days prior to the first dose of trial treatment, 6. Known history of active Bacillus Tuberculosis (TB), 7. Hypersensitivity to pembrolizumab or any of its excipients, 8. Any contraindication for receiving a treatment of docetaxel, cisplatin, 5-fluorouracil or carboplatin, 9. Hearing impairment or cardiorespiratory pathology with a contraindication of overhydration, 10. Currently received prophylactic treatment of phenytoin which could have an interaction with cisplatin, 5-fluorouracile or carboplatin or fosphenytoin which could have an interaction with carboplatin, 11. Currently received treatment of sorivudine or analogues (e.g. brivudine) with could have an interaction with 5-fluorouracile, 12. Complete known dihydropyrimidine dehydrogenase deficiency (DPD), 13. Clinically active cardiac disease or myocardial infarction within 6 months prior to the first dose of treatment, 14. Known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer, 15. Active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease-modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg. thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc…) is not considered a form of systemic treatment, 16. History of (non-infectious) pneumonitis that required steroids, evidence of interstitial lung disease or active, non-infectious pneumonitis, 17. Active infection requiring systemic therapy, 18. History or current evidence of any condition, therapy, or laboratory abnormality that might influence the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator, 19. Known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial, 20. Is pregnant or breastfeeding, or expecting to conceive children within the projected duration of the trial, starting with the pre-screening or screening visit through 180 days after the last dose of trial treatment, 21. Received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent, 22. Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA [qualitative] is detected), 23. Received a live vaccine within 30 days of planned start of study therapy. Note: Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed. However, intranasal influenza vaccines (e.g., Flu-Mist®) are live attenuated vaccines, and are not allowed, 24. Received prior organ transplant which may include an allogenic stem cell transplant, 25. People particularly vulnerable as defined in Articles L.1121-5 to -8 of the French Healthcare Code, including: person deprived of freedom by an administrative or judicial decision, adult being the object of a legal protection measure or outside a state to express their consent, pregnant or breastfeeding women. |
Country | Name | City | State |
---|---|---|---|
France | PEYRADE Frédéric | Nice |
Lead Sponsor | Collaborator |
---|---|
Centre Antoine Lacassagne | GERCOR - Multidisciplinary Oncology Cooperative Group, GORTEC |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Phase I : Evaluation of Recommended dose for phase II and characterization of the safety and tolerability profile of pembrolizumab when administered in combination with docetaxel, cisplatin and 5 Fluorouracil | To evaluate by using a "3+3 modified schedule" the Recommended Phase 2 Dose (RPD2), Dose Limiting Toxicities (DLT) and Maximal Tolerated Dose (MTD) of the association of pembrolizumab with induction therapy by docetaxel, cisplatin and 5-fluorouracil (TP²F) as first-line treatment for patients with locally-advanced unresectable HNSCC | 12 months post treatment | |
Primary | Phase II : Progression-free survival | Progression-free survival : To evaluate, in terms of progression-free survival rate at 12 months, the efficacy of the association of pembrolizumab with induction therapy by docetaxel, cisplatin and 5-fluorouracil (TP²F) as first-line treatment for patients with locally-advanced unresectable HNSCC ; in order to demonstrate that the addition of pembrolizumab to TPF can increase efficacy without increasing toxicity. | 12 months post treatment | |
Secondary | Phase I : Antitumor activity | To document any antitumor activity observed with pembrolizumab in combination with docetaxel, cisplatin and 5 Fluorouracil | 24 months post treatment | |
Secondary | Phase II : Overall survival rate | Overall survival rate at 2 years. It will be calculated from the date of study inclusion to the date of the event or to the last known contact of the patient, for those still event free at the time of the last follow-up until 24 months post treatment. | 24 months post treatment | |
Secondary | Phase II : Best Overall response | Best overall response rate after induction chemotherapy : Partial Response or Complete Response or Stable Disease after induction chemotherapy (qualitative data) | 24 months post treatment | |
Secondary | Phase II : Best Overall response | Best overall response rate after radiation therapy: Partial Response or Complete Response or Stable Disease after radiation therapy (qualitative data) | 24 months post treatment | |
Secondary | Phase II : Objective response rate | Objective response rate (ORR) will be determinated by evaluation of Complete Response (CR) and Partial Response (PR) | 24 months post treatment | |
Secondary | Phase II : Progression-free survival (PFS) at 12 months | Progression-free survival (PFS) is defined by disease recurrence. It will be calculated from the date of study inclusion to the date of the event or to the last known contact of the patient, for those still event free at the time of the last follow-up until 12 months after the treatment. | 12 months | |
Secondary | Phase II : Level of expression of PD1 before and after treatment | Level of expression of PD1 will be determinated by using quantitative and qualitative data before and after treatment | 7 weeks | |
Secondary | Phase II : Evaluation of Safety | Toxicity will be evaluated according to NCI-CTCAE v4.03 | 24 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT02211027 -
Biological Vaccine: Semi-allogeneic Human Fibroblasts (MRC-5) Transfected With DNA
|
Phase 1 | |
Recruiting |
NCT04083599 -
GEN1042 Safety Trial and Anti-tumor Activity in Subjects With Malignant Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03735628 -
An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05891171 -
Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers
|
Phase 1 | |
Recruiting |
NCT03546582 -
SBRT +/- Pembrolizumab in Patients With Local-Regionally Recurrent or Second Primary Head and Neck Carcinoma
|
Phase 2 | |
Not yet recruiting |
NCT06102447 -
Efficacy and Safety of Netupitant and Palonosetron Hydrochloride Capsules in Preventing Nausea and Vomiting Induced by Radiochemotherapy in Head and Neck Squamous Cell Carcinoma
|
N/A | |
Terminated |
NCT00911326 -
Evaluation of Sentinel Lymph Nodes in Head and Neck Squamous Cell Carcinoma
|
Phase 3 | |
Recruiting |
NCT06295731 -
INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC
|
Phase 2/Phase 3 | |
Completed |
NCT04220866 -
Study of Intratumoral (IT) Ulevostinag (MK-1454) in Combination With Intravenous (IV) Pembrolizumab (MK-3475) Compared to IV Pembrolizumab Alone as the First Line Treatment of Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) (MK-1454-002)
|
Phase 2 | |
Completed |
NCT02764593 -
Safety Testing of Adding Nivolumab to Chemotherapy in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck Cancer
|
Phase 1 | |
Withdrawn |
NCT04849377 -
RBD-HPV: Risk-Based De-Intensification for HPV+ HNSCC
|
Phase 2 | |
Completed |
NCT03268993 -
Effects of Avmacol® in the Oral Mucosa of Patients Following Curative Treatment for Tobacco-related Head and Neck Cancer
|
N/A | |
Recruiting |
NCT04284540 -
Hypofractionated Radiotherapy in Elderly Patients With Head & Neck Squamous Cell Carcinoma
|
N/A | |
Recruiting |
NCT04080804 -
Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer
|
Phase 2 | |
Active, not recruiting |
NCT04215978 -
Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT03746431 -
A Phase 1/2 Study of [225Ac]-FPI-1434 Injection
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05249426 -
A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer
|
Phase 1 | |
Not yet recruiting |
NCT05473156 -
A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected Malignancies
|
Phase 1/Phase 2 | |
Completed |
NCT02684253 -
Screening Trial of Nivolumab With Image Guided, Stereotactic Body Radiotherapy (SBRT) Versus Nivolumab Alone in Patients With Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
|
Phase 2 | |
Terminated |
NCT03276819 -
A Clinical and Biological Umbrella Protocol for Smoker or Non-smoker Patients With OPML or HNSCC
|
N/A |